Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity

Nicole K. Paulk, Katja Pekrun, Erhua Zhu, Sean Nygaard, Bin Li, Jianpeng Xu, Kirk Chu, Christian Leborgne, Allison P. Dane, Annelise Haft, Yue Zhang, Feijie Zhang, Chris Morton, Marcus B. Valentine, Andrew M. Davidoff, Amit C. Nathwani, Federico Mingozzi, Markus Grompe, Ian E. Alexander, Leszek LisowskiMark A. Kay

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Existing recombinant adeno-associated virus (rAAV) serotypes for delivering in vivo gene therapy treatments for human liver diseases have not yielded combined high-level human hepatocyte transduction and favorable humoral neutralization properties in diverse patient groups. Yet, these combined properties are important for therapeutic efficacy. To bioengineer capsids that exhibit both unique seroreactivity profiles and functionally transduce human hepatocytes at therapeutically relevant levels, we performed multiplexed sequential directed evolution screens using diverse capsid libraries in both primary human hepatocytes in vivo and with pooled human sera from thousands of patients. AAV libraries were subjected to five rounds of in vivo selection in xenografted mice with human livers to isolate an enriched human-hepatotropic library that was then used as input for a sequential on-bead screen against pooled human immunoglobulins. Evolved variants were vectorized and validated against existing hepatotropic serotypes. Two of the evolved AAV serotypes, NP40 and NP59, exhibited dramatically improved functional human hepatocyte transduction in vivo in xenografted mice with human livers, along with favorable human seroreactivity profiles, compared with existing serotypes. These novel capsids represent enhanced vector delivery systems for future human liver gene therapy applications. Paulk et al. performed sequential directed evolution screens of AAV capsid libraries in primary human hepatocytes in vivo and against human sera from thousands of patients. Resultant capsid variants AAV-NP40, AAV-NP59, and AAV-NP84 exhibit unique seroreactivity and significantly increase functional human hepatocyte transduction in vivo compared to existing hepatotropic serotypes.

Original languageEnglish (US)
JournalMolecular Therapy
DOIs
StateAccepted/In press - 2017

Fingerprint

Capsid
Liver
Hepatocytes
Genetic Therapy
Libraries
Dependovirus
Serum
Immunoglobulins
Liver Diseases

Keywords

  • AAV
  • Evolution
  • Hepatocyte
  • Human
  • Library
  • Liver
  • Neutralization
  • Screen
  • Transduction

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. / Paulk, Nicole K.; Pekrun, Katja; Zhu, Erhua; Nygaard, Sean; Li, Bin; Xu, Jianpeng; Chu, Kirk; Leborgne, Christian; Dane, Allison P.; Haft, Annelise; Zhang, Yue; Zhang, Feijie; Morton, Chris; Valentine, Marcus B.; Davidoff, Andrew M.; Nathwani, Amit C.; Mingozzi, Federico; Grompe, Markus; Alexander, Ian E.; Lisowski, Leszek; Kay, Mark A.

In: Molecular Therapy, 2017.

Research output: Contribution to journalArticle

Paulk, NK, Pekrun, K, Zhu, E, Nygaard, S, Li, B, Xu, J, Chu, K, Leborgne, C, Dane, AP, Haft, A, Zhang, Y, Zhang, F, Morton, C, Valentine, MB, Davidoff, AM, Nathwani, AC, Mingozzi, F, Grompe, M, Alexander, IE, Lisowski, L & Kay, MA 2017, 'Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity', Molecular Therapy. https://doi.org/10.1016/j.ymthe.2017.09.021
Paulk, Nicole K. ; Pekrun, Katja ; Zhu, Erhua ; Nygaard, Sean ; Li, Bin ; Xu, Jianpeng ; Chu, Kirk ; Leborgne, Christian ; Dane, Allison P. ; Haft, Annelise ; Zhang, Yue ; Zhang, Feijie ; Morton, Chris ; Valentine, Marcus B. ; Davidoff, Andrew M. ; Nathwani, Amit C. ; Mingozzi, Federico ; Grompe, Markus ; Alexander, Ian E. ; Lisowski, Leszek ; Kay, Mark A. / Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. In: Molecular Therapy. 2017.
@article{eef5ca07cf5048db92fe4f8eb26d4b2d,
title = "Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity",
abstract = "Existing recombinant adeno-associated virus (rAAV) serotypes for delivering in vivo gene therapy treatments for human liver diseases have not yielded combined high-level human hepatocyte transduction and favorable humoral neutralization properties in diverse patient groups. Yet, these combined properties are important for therapeutic efficacy. To bioengineer capsids that exhibit both unique seroreactivity profiles and functionally transduce human hepatocytes at therapeutically relevant levels, we performed multiplexed sequential directed evolution screens using diverse capsid libraries in both primary human hepatocytes in vivo and with pooled human sera from thousands of patients. AAV libraries were subjected to five rounds of in vivo selection in xenografted mice with human livers to isolate an enriched human-hepatotropic library that was then used as input for a sequential on-bead screen against pooled human immunoglobulins. Evolved variants were vectorized and validated against existing hepatotropic serotypes. Two of the evolved AAV serotypes, NP40 and NP59, exhibited dramatically improved functional human hepatocyte transduction in vivo in xenografted mice with human livers, along with favorable human seroreactivity profiles, compared with existing serotypes. These novel capsids represent enhanced vector delivery systems for future human liver gene therapy applications. Paulk et al. performed sequential directed evolution screens of AAV capsid libraries in primary human hepatocytes in vivo and against human sera from thousands of patients. Resultant capsid variants AAV-NP40, AAV-NP59, and AAV-NP84 exhibit unique seroreactivity and significantly increase functional human hepatocyte transduction in vivo compared to existing hepatotropic serotypes.",
keywords = "AAV, Evolution, Hepatocyte, Human, Library, Liver, Neutralization, Screen, Transduction",
author = "Paulk, {Nicole K.} and Katja Pekrun and Erhua Zhu and Sean Nygaard and Bin Li and Jianpeng Xu and Kirk Chu and Christian Leborgne and Dane, {Allison P.} and Annelise Haft and Yue Zhang and Feijie Zhang and Chris Morton and Valentine, {Marcus B.} and Davidoff, {Andrew M.} and Nathwani, {Amit C.} and Federico Mingozzi and Markus Grompe and Alexander, {Ian E.} and Leszek Lisowski and Kay, {Mark A.}",
year = "2017",
doi = "10.1016/j.ymthe.2017.09.021",
language = "English (US)",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity

AU - Paulk, Nicole K.

AU - Pekrun, Katja

AU - Zhu, Erhua

AU - Nygaard, Sean

AU - Li, Bin

AU - Xu, Jianpeng

AU - Chu, Kirk

AU - Leborgne, Christian

AU - Dane, Allison P.

AU - Haft, Annelise

AU - Zhang, Yue

AU - Zhang, Feijie

AU - Morton, Chris

AU - Valentine, Marcus B.

AU - Davidoff, Andrew M.

AU - Nathwani, Amit C.

AU - Mingozzi, Federico

AU - Grompe, Markus

AU - Alexander, Ian E.

AU - Lisowski, Leszek

AU - Kay, Mark A.

PY - 2017

Y1 - 2017

N2 - Existing recombinant adeno-associated virus (rAAV) serotypes for delivering in vivo gene therapy treatments for human liver diseases have not yielded combined high-level human hepatocyte transduction and favorable humoral neutralization properties in diverse patient groups. Yet, these combined properties are important for therapeutic efficacy. To bioengineer capsids that exhibit both unique seroreactivity profiles and functionally transduce human hepatocytes at therapeutically relevant levels, we performed multiplexed sequential directed evolution screens using diverse capsid libraries in both primary human hepatocytes in vivo and with pooled human sera from thousands of patients. AAV libraries were subjected to five rounds of in vivo selection in xenografted mice with human livers to isolate an enriched human-hepatotropic library that was then used as input for a sequential on-bead screen against pooled human immunoglobulins. Evolved variants were vectorized and validated against existing hepatotropic serotypes. Two of the evolved AAV serotypes, NP40 and NP59, exhibited dramatically improved functional human hepatocyte transduction in vivo in xenografted mice with human livers, along with favorable human seroreactivity profiles, compared with existing serotypes. These novel capsids represent enhanced vector delivery systems for future human liver gene therapy applications. Paulk et al. performed sequential directed evolution screens of AAV capsid libraries in primary human hepatocytes in vivo and against human sera from thousands of patients. Resultant capsid variants AAV-NP40, AAV-NP59, and AAV-NP84 exhibit unique seroreactivity and significantly increase functional human hepatocyte transduction in vivo compared to existing hepatotropic serotypes.

AB - Existing recombinant adeno-associated virus (rAAV) serotypes for delivering in vivo gene therapy treatments for human liver diseases have not yielded combined high-level human hepatocyte transduction and favorable humoral neutralization properties in diverse patient groups. Yet, these combined properties are important for therapeutic efficacy. To bioengineer capsids that exhibit both unique seroreactivity profiles and functionally transduce human hepatocytes at therapeutically relevant levels, we performed multiplexed sequential directed evolution screens using diverse capsid libraries in both primary human hepatocytes in vivo and with pooled human sera from thousands of patients. AAV libraries were subjected to five rounds of in vivo selection in xenografted mice with human livers to isolate an enriched human-hepatotropic library that was then used as input for a sequential on-bead screen against pooled human immunoglobulins. Evolved variants were vectorized and validated against existing hepatotropic serotypes. Two of the evolved AAV serotypes, NP40 and NP59, exhibited dramatically improved functional human hepatocyte transduction in vivo in xenografted mice with human livers, along with favorable human seroreactivity profiles, compared with existing serotypes. These novel capsids represent enhanced vector delivery systems for future human liver gene therapy applications. Paulk et al. performed sequential directed evolution screens of AAV capsid libraries in primary human hepatocytes in vivo and against human sera from thousands of patients. Resultant capsid variants AAV-NP40, AAV-NP59, and AAV-NP84 exhibit unique seroreactivity and significantly increase functional human hepatocyte transduction in vivo compared to existing hepatotropic serotypes.

KW - AAV

KW - Evolution

KW - Hepatocyte

KW - Human

KW - Library

KW - Liver

KW - Neutralization

KW - Screen

KW - Transduction

UR - http://www.scopus.com/inward/record.url?scp=85031746439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031746439&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2017.09.021

DO - 10.1016/j.ymthe.2017.09.021

M3 - Article

C2 - 29055620

AN - SCOPUS:85031746439

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

ER -